Clinical Trials Logo

Clinical Trial Summary

Background: - Li Fraumeni Syndrome (LFS) is a highly penetrant, autosomal dominant cancer predisposition disorder. Four main cancer types including sarcoma, adrenocortical carcinoma, breast cancer, and malignant brain tumors commonly characterize LFS but the syndrome can include other cancers. - Metformin is an oral biguanide drug that is approved by the FDA for the treatment of type II diabetes. Metformin has been associated with reduced cancer risk in several epidemiologic studies and reduced cancer mortality in patients with type 2 diabetes. - Metformin decreases circulating insulin and IGF1, and promotes glucose uptake in skeletal muscle and inhibits gluconeogenesis in the liver. Elevations in circulating insulin and IGF1 levels have been associated with increased cancer risk. - Preclinical research in animal models shows that metformin may be more toxic in cancer cells that have lost p53 function. - Lifetime risk of cancer in LFS patients with germline TP53 mutations is estimated to be up to 70% by age 60, with women having excess lifetime cancer risk (up to 100%) compared to men (up to 80%). There are currently no approved chemopreventive agents for patients with LFS. - Metformin has been shown to be safe and tolerable in diabetic and non-diabetics, and may be an ideal candidate for chemoprevention of cancer in this population. Objectives: - Determine the tolerability of oral daily metformin in patients with LFS caused by germline TP53 mutations. - Determine if 8 weeks of daily metformin administration has any effect on circulating IGF-1, insulin, and IGFBP3 Eligibility: - Must have a germline TP53 mutation and provide documentation of testing. - Must have adequate organ function. - Age greater than or equal to 18 years. Design: - This is a pilot study to assess the tolerability of daily oral metformin administration in patients with LFS caused by germline TP53 mutations and to study the effect of metformin on biomarker levels in these subjects. - In the absence of intolerable toxicity, a minimum of 22 patients will take metformin by mouth for a total of 14 weeks and then discontinue metformin for 6 weeks. The total time on study will be 20 weeks. - Patients will be assessed for biomarker levels (IGF-1, insulin, IGFBP3) by blood sample at baseline, and weeks 0 and 8.


Clinical Trial Description

Background: - Li Fraumeni Syndrome (LFS) is a highly penetrant, autosomal dominant cancer predisposition disorder. Four main cancer types including sarcoma, adrenocortical carcinoma, breast cancer, and malignant brain tumors commonly characterize LFS but the syndrome can include other cancers. - Metformin is an oral biguanide drug that is approved by the FDA for the treatment of type II diabetes. Metformin has been associated with reduced cancer risk in several epidemiologic studies and reduced cancer mortality in patients with type 2 diabetes. - Metformin decreases circulating insulin and IGF1, and promotes glucose uptake in skeletal muscle and inhibits gluconeogenesis in the liver. Elevations in circulating insulin and IGF1 levels have been associated with increased cancer risk. - Preclinical research in animal models shows that metformin may be more toxic in cancer cells that have lost p53 function. - Lifetime risk of cancer in LFS patients with germline TP53 mutations is estimated to be up to 70% by age 60, with women having excess lifetime cancer risk (up to 100%) compared to men (up to 80%). There are currently no approved chemopreventive agents for patients with LFS. - Metformin has been shown to be safe and tolerable in diabetic and non-diabetics, and may be an ideal candidate for chemoprevention of cancer in this population. Objectives: - Determine the tolerability of oral daily metformin in patients with LFS caused by germline TP53 mutations. - Determine if 8 weeks of daily metformin administration has any effect on circulating IGF-1, insulin, and IGFBP3 Eligibility: - Must have a germline TP53 mutation and provide documentation of testing. - Must have adequate organ function. - Age greater than or equal to 18 years. Design: - This is a pilot study to assess the tolerability of daily oral metformin administration in patients with LFS caused by germline TP53 mutations and to study the effect of metformin on biomarker levels in these subjects. - In the absence of intolerable toxicity, a minimum of 22 patients will take metformin by mouth for a total of 14 weeks and then discontinue metformin for 6 weeks. The total time on study will be 20 weeks. - Patients will be assessed for biomarker levels (IGF-1, insulin, IGFBP3) by blood sample at baseline, and weeks 0, 8, 14 and 20. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01981525
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 1
Start date January 27, 2014
Completion date December 11, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04367246 - Li-Fraumeni Syndrome/TP53 Biobank
Recruiting NCT04541654 - Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Completed NCT01737255 - Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
Recruiting NCT05126810 - Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
Active, not recruiting NCT02950987 - Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes N/A
Enrolling by invitation NCT03176836 - Li-Fraumeni Syndrome Imaging Study N/A
Recruiting NCT01143454 - Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Completed NCT02289326 - Biomarker Monitoring in TP53 Mutation Carriers
Recruiting NCT04982744 - Registry of Li Fraumeni and Li Fraumeni Like Syndromes
Completed NCT00406445 - Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
Recruiting NCT01443468 - Clinical and Genetic Studies of Li-Fraumeni Syndrome
Completed NCT04966923 - Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
Recruiting NCT06088030 - Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer Phase 2
Recruiting NCT03050268 - Familial Investigations of Childhood Cancer Predisposition